Expert Insights on Genomic Test Selection in Breast Cancer: Strategies for Node-Negative vs Node-Positive Disease

Clinical Factors Influencing Test Selection

Main Discussion Topics:

• Impact of nodal status, tumor size, and menopausal status on genomic test selection
• Interpretation of TAILORx and RxPONDER trial results in clinical practice
• Considerations for neoadjuvant therapy selection based on genomic testing

Key Points for Physicians:

• For ER+/HER2– patients, TAILORx and RxPONDER trial results guide decision-making for node-negative and node-positive patients respectively.
• The 16 to 24 recurrence score range in premenopausal patients requires nuanced shared decision-making.
• Neoadjuvant endocrine therapy may be underutilized for larger tumors with favorable biology.

Notable Insights:

• Genomic assays can help determine whether large ER+/HER2– tumors would benefit more from neoadjuvant chemotherapy or endocrine therapy.
• Recurrence score confidence intervals for node-negative groups and groups with 1 to 3 positive nodes overlap substantially

Clinical Significance: Clinical factors such as nodal status, tumor size, and menopausal status must be integrated with genomic test results to optimize treatment decision-making, particularly for premenopausal patients with intermediate recurrence scores.